PT3197456T - Tratamentos de cancro - Google Patents

Tratamentos de cancro

Info

Publication number
PT3197456T
PT3197456T PT157262585T PT15726258T PT3197456T PT 3197456 T PT3197456 T PT 3197456T PT 157262585 T PT157262585 T PT 157262585T PT 15726258 T PT15726258 T PT 15726258T PT 3197456 T PT3197456 T PT 3197456T
Authority
PT
Portugal
Prior art keywords
cancer treatments
treatments
cancer
Prior art date
Application number
PT157262585T
Other languages
English (en)
Portuguese (pt)
Inventor
Griffith Hugh
Mcguigan Chris
Pepper Chris
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53276184&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3197456(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by NuCana plc filed Critical NuCana plc
Publication of PT3197456T publication Critical patent/PT3197456T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT157262585T 2015-05-14 2015-05-14 Tratamentos de cancro PT3197456T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15726258.5A EP3197456B2 (en) 2015-05-14 2015-05-14 Cancer treatments
PCT/GB2015/051438 WO2016181093A1 (en) 2015-05-14 2015-05-14 Cancer treatments

Publications (1)

Publication Number Publication Date
PT3197456T true PT3197456T (pt) 2018-05-22

Family

ID=53276184

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157262585T PT3197456T (pt) 2015-05-14 2015-05-14 Tratamentos de cancro

Country Status (26)

Country Link
US (3) US20180289733A1 (enExample)
EP (2) EP3197456B2 (enExample)
JP (1) JP6761852B2 (enExample)
KR (1) KR20180021697A (enExample)
CN (2) CN107835687A (enExample)
AU (2) AU2015394135B2 (enExample)
BR (1) BR112017024461B1 (enExample)
CA (1) CA2985540C (enExample)
CY (1) CY1120516T1 (enExample)
DK (1) DK3197456T3 (enExample)
EA (1) EA201792509A1 (enExample)
ES (1) ES2668377T3 (enExample)
HR (1) HRP20180762T1 (enExample)
HU (1) HUE038541T2 (enExample)
IL (1) IL255591B (enExample)
LT (1) LT3197456T (enExample)
MX (2) MX390506B (enExample)
MY (1) MY192081A (enExample)
PH (1) PH12017502086B1 (enExample)
PL (1) PL3197456T3 (enExample)
PT (1) PT3197456T (enExample)
RS (1) RS57371B1 (enExample)
SI (1) SI3197456T1 (enExample)
SM (1) SMT201800303T1 (enExample)
TR (1) TR201806642T4 (enExample)
WO (1) WO2016181093A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
ES2569185T3 (es) 2011-03-01 2016-05-09 Nucana Biomed Limited Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer
AU2013346515B2 (en) 2012-11-16 2017-05-25 NuCana plc Process for preparing nucleoside prodrugs
EA033046B1 (ru) 2014-06-25 2019-08-30 НУКАНА ПиЭлСи Состав, содержащий пролекарство гемцитабина
RS60968B1 (sr) 2014-06-25 2020-11-30 NuCana plc Prolekovi gemcitabina
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
HRP20191461T1 (hr) 2014-11-28 2019-11-15 NuCana plc Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja
EP3353201B1 (en) 2015-09-25 2021-09-08 F. Hoffmann-La Roche AG Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof
PH12018500691B1 (en) 2015-10-05 2022-08-10 NuCana plc Combination therapy
CA3007347C (en) 2015-12-11 2020-08-04 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
SI3393478T1 (sl) * 2015-12-23 2020-07-31 NuCana plc Kombinacijska terapija
KR102566461B1 (ko) * 2015-12-23 2023-08-14 뉴카나 피엘씨 조합 요법
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
EP3863674A2 (en) * 2018-10-12 2021-08-18 The Regents of the University of Colorado, a body corporate Compositions and methods for reducing cancer stem cells
CN114533739B (zh) * 2021-01-31 2023-12-29 兰州大学 核苷类似物在制备预防或治疗胃肠道疾病药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
JP2011522515A (ja) * 2008-04-10 2011-08-04 マサチューセッツ インスティテュート オブ テクノロジー 癌幹細胞を標的とする薬剤を同定する方法およびその使用

Also Published As

Publication number Publication date
JP2018515618A (ja) 2018-06-14
AU2015394135B2 (en) 2021-09-16
US20230226092A1 (en) 2023-07-20
CN107835687A (zh) 2018-03-23
EP3415149A1 (en) 2018-12-19
MX374946B (es) 2025-03-06
KR20180021697A (ko) 2018-03-05
BR112017024461A2 (pt) 2018-07-24
CA2985540A1 (en) 2016-11-17
CY1120516T1 (el) 2019-07-10
HUE038541T2 (hu) 2018-10-29
IL255591B (en) 2021-10-31
CN115837028A (zh) 2023-03-24
MX2017014544A (es) 2018-09-26
JP6761852B2 (ja) 2020-09-30
US20210100825A1 (en) 2021-04-08
RS57371B1 (sr) 2018-08-31
BR112017024461B1 (pt) 2023-04-04
LT3197456T (lt) 2018-07-10
EP3197456A1 (en) 2017-08-02
MX2020009154A (es) 2022-03-08
AU2015394135A1 (en) 2017-12-14
EA201792509A1 (ru) 2018-05-31
DK3197456T3 (en) 2018-06-06
IL255591A (en) 2018-01-31
US20180289733A1 (en) 2018-10-11
WO2016181093A1 (en) 2016-11-17
PL3197456T3 (pl) 2018-09-28
EP3197456B2 (en) 2023-10-11
CA2985540C (en) 2021-08-24
SMT201800303T1 (it) 2018-07-17
HRP20180762T1 (hr) 2018-08-24
ES2668377T3 (es) 2018-05-17
EP3197456B1 (en) 2018-04-04
PH12017502086A1 (en) 2018-04-30
MX390506B (es) 2025-03-20
PH12017502086B1 (en) 2022-12-09
AU2021277614A1 (en) 2021-12-23
TR201806642T4 (tr) 2018-06-21
SI3197456T1 (en) 2018-08-31
MY192081A (en) 2022-07-26

Similar Documents

Publication Publication Date Title
IL296080B1 (en) Method for treating cancer
IL255261A0 (en) Methods for treating cancer
IL261468A (en) Uterine cancer treatments
EP3463464A4 (en) ASSOCIATION TREATMENT
SI3283527T1 (sl) Kombinirana terapija proti raku
EP3291824A4 (en) ANTIMICROBIAL THERAPY
DK3240801T3 (da) Kombinationstumorimmunterapi
PL3197456T3 (pl) Leczenie nowotworów
IL258684A (en) Combination therapy for treating malignancies
IL263123A (en) Cancer treatments
PL3171891T3 (pl) Sposób
KR20180084772A (ko) 암 치료를 위한 조합 치료법
IL265697B1 (en) Treatment of prostate cancer
PL3458052T3 (pl) Leczenie skojarzone nowotworu
EP3413927A4 (en) CANCER THERAPY
EP3546020C0 (en) CANCER TREATMENT DEVICE
EP3593139C0 (en) CANCER BIOMARKERS
DK3576740T3 (da) Cancerbehandling
HUE040167T2 (hu) Rákkezelés
EP3576791A4 (en) CALRETICULIN-MEDIATION CANCER TREATMENT
EP3362091A4 (en) COMBINATION THERAPY
DK3393478T3 (da) Kombinationsterapi
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
DK3407909T3 (da) Cancerbehandling
DK3277325T3 (da) Kombinationsimmunterapi for cancer